donanemab approved Kisunla
Selected indexed studies
- Donanemab: Appropriate use recommendations. (J Prev Alzheimers Dis, 2025) [PMID:40155270]
- Lecanemab: Appropriate Use Recommendations. (J Prev Alzheimers Dis, 2023) [PMID:37357276]
- Donanemab: First Approval. (Drugs, 2024) [PMID:39237715]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Alzheimer's Disease: Treatment Challenges for the Future. (2025) pubmed
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis. (2024) pubmed
- Donanemab: Appropriate use recommendations. (2025) pubmed
- Donanemab: First Approval. (2024) pubmed
- Lecanemab: Appropriate Use Recommendations. (2023) pubmed
- Treatment of Alzheimer Disease. (2024) pubmed
- A 2025 update on treatment strategies for the Alzheimer's disease spectrum. (2025) pubmed
- Donanemab for Alzheimer's disease: from preclinical research to the clinical application. (2025) pubmed
- Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives. (2025) pubmed
- Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. (2022) pubmed